This study presents the findings of a national survey of physicians about their knowledge of biosimilar biological products as well as the impact of biological product naming conventions on prescriber choice.
Related Products
Prescription Drugs
Reports
Displaying 31 - 40 of 78. 10 per page. Page 4.
Advanced SearchPhysician Understanding and Willingness to Prescribe Biosimilars: Findings from a US National Survey
ASPE Issue Brief
Use of Outpatient Pharmacological Treatment Among Infants Born with Neonatal Abstinence Syndrome: Medicaid 2008-2017 Issue Brief
Use of Outpatient Pharmacological Treatment Among Infants Born with Neonatal Abstinence Syndrome: Medicaid 2008-2017 ASPE ISSUE BRIEF Mir M. Ali, Emma Nye, and Kristina West U.S. Department of Health and Human Services
ASPE Issue Brief
Trends in Hospital Readmission and Emergency Department Visit among Infants Born with Neonatal Abstinence Syndrome Issue Brief
Trends in Hospital Readmission and Emergency Department Visit among Infants Born with Neonatal Abstinence Syndrome ASPE ISSUE BRIEF Mir M. Ali, Emma Nye, and Kristina West U.S. Department of Health and Human Services
ASPE Issue Brief
How Does DATA-Waiver Provider Patient Capacity Relate to Opioid and Buprenorphine Prescribing? Issue Brief
How Does DATA-Waiver Provider Patient Capacity Relate to Opioid and Buprenorphine Prescribing? Issue Brief Robin Ghertner and Mir M. Ali U.S. Department of Health and Human Services
ASPE Issue Brief
Postpartum Opioid Prescription Fills, Opioid Use Disorder, and Utilization of Medication-Assisted Treatment among Women with Medicaid and Private Health Insurance Coverage Issue Brief
Postpartum Opioid Prescription Fills, Opioid Use Disorder, and Utilization of Medication-Assisted Treatment among Women with Medicaid and Private Health Insurance Coverage Issue Brief Mir M. Ali, Kristina West, and Emma Nye U.S. Department of Health and Human Services
Report to Congress
Report to Congress: Prescription Drug Pricing Report
The Secretary of Health and Human Services (HHS) has been directed to submit a drug pricing report containing information requested by the House Committee on Appropriations.
ASPE Issue Brief
Optimal Utilization of Psychosocial Supports in Medication-Assisted Treatment for Opioid Use Disorder Issue Brief
Westat Printer Friendly Version in PDF Format (3 PDF pages)
ASPE Issue Brief
Optimal Utilization of Psychosocial Supports in Medication-Assisted Treatment for Opioid Use Disorder Issue Brief
As the opioid epidemic has evolved into a national crisis, the need for treatment has increased greatly. Medication-assisted treatment (MAT) is a “whole-patient” approach to the treatment of opioid use disorder (OUD) that combines the use of medications and psychosocial supports, such as therapy, counseling, self-help groups, and case management.
Public Listing Status of Data-Waivered Providers: Data Brief
Printer Friendly Version in PDF Format (3 PDF pages)
ASPE Issue Brief
Assessing the Costs and Benefits of Extending Coverage of Immunosuppressive Drugs under Medicare
By statute, the majority of patients with end-stage renal disease (ESRD) are eligible for Medicare, regardless of age. Kidney transplantation is ultimately considered the best treatment for ESRD, but ESRD-related eligibility for Medicare coverage extends for only 36 months post-transplant.